Multiple Sclerosis Drug Market Size

Multiple Sclerosis Drug Market size was over USD 25.07 billion in 2024 and is expected to exceed USD 42.07 billion by the end of 2037, growing at over 4.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of multiple sclerosis drug is evaluated at USD 25.89 billion. The market growth is primarily driven by the rising number of new drug candidates for multiple sclerosis being developed and pre-clinical trials are ongoing. Worldwide, nearly 3 million people are living with multiple sclerosis. Therefore, an increase in the number of sclerosis patients is expected to result in a rise in the need for medications and medical care.

The efficacy of the medicines and surging development in the treatment of multiple sclerosis are expected to boost market growth. In June 2021, Bristol Myer Squibb released the progressive result of the early Zepsosia treatment, nearly, 80% of patients with high thalamic volume benefitted from the drug. Furthermore, proactive government efforts for multiple sclerosis patients are expected to propel the growth of the global multiple sclerosis drug market. In India, the government proposed to add multiple sclerosis in the Ayushman Bharat Scheme, a Nation Health Protection Mission, this initiative is to reduce the cost of treatment in the country. Moreover, in China as well, the government added multiple sclerosis to the list of rare diseases to improve the treatment outcomes of the patient.